I believe Cadence is in the building phase in 2011. Right now it is not the sales but formulary acceptance. I am comfortable with 900-1000 hospitals by the end of the 2nd qtr.
I see sales around 2 million give or take 100,000 dollars. Doctors are so used to using opoids in this country that they are reluctant to switch or use less opoids. The FDA may be Cadence's best ally here since they are concerned about over usage of opoids.For the rest of 2011 they must educate the doctors on how to use Ofirmev. I do expect to see a big uptick in the 4th qtr around $10 million. This will set Cadence up for a great 2012. Looking for $100 million in 2012.
We have a 12 room OR and use between 15 to 30 vials every day. Ofirmev is already incorporated into pre and post op orders for most surgical patients here. We are also using it at the surgery center, where it costs more than the $10/vial hospital price. IV Ketorolac and Ofirmev are two narcotic sparing pain drugs, but the latter has much less contraindications. Chances are if a patient gets IV ketorolac, then Ofirmev is also indicated, to further reduce the need for opiates.
Turning over the beds is what is all about in the hospital setting. Gone are the hospitals that have 500-600 beds. A Lot have downsized to to 300-350 beds and operate with efficiency in turning over the beds.
I still don't get your point. obviously IV Tylenol will be used in those who can't take PO. so what's the point of comparing it to the PO medication?
also, ketorolac is an NSAId. the point is that there are many situations that limit ketorolac's usage, and in those cases Ofirmev will be an ideal alternative.